论文部分内容阅读
目的:探讨辛芷鼻敏胶囊对变应性鼻炎(AR)大鼠骨髓及外周血中IL-5和外周血及骨髓中嗜酸性粒细胞(EOS)的影响。方法:用卵清蛋白(OVA)致敏SD大鼠制成模型,分正常对照组、模型组、鼻炎康组、辛芷鼻敏胶囊组,分别ig生理盐水、鼻炎康片(3 g·kg-1)和辛芷鼻敏胶囊(3.6 g·kg-1),连续10 d。采用双抗体夹心酶联免疫吸附技术(ELISA)定量测定骨髓及外周血中白介素-5(IL-5)含量,骨髓和外周血涂片瑞氏染色计数EOS。结果:辛芷鼻敏胶囊组骨髓及外周血中IL-5,EOS比模型组有显著降低(P<0.05),且与鼻炎康组比较有统计学意义(P<0.05);辛芷鼻敏胶囊组大鼠鼻黏膜EOS计数明显低于模型组和鼻炎康组(P<0.01,P<0.05)。结论:辛芷鼻敏胶囊可以减少IL-5水平,减少嗜酸性粒细胞浸润,而起到一定的治疗作用。
Objective: To investigate the effect of Xinzhi Bimin Capsule on IL-5 and eosinophil (EOS) in bone marrow and peripheral blood of patients with allergic rhinitis (AR). Methods: SD rats were sensitized with ovalbumin (OVA) and divided into normal control group, model group, rhinitis group, Xinzhibimin capsule group, ig saline, rhinitis tablet (3 g · kg -1) and Xinzhi bimin capsules (3.6 g · kg-1) for 10 days. The levels of interleukin-5 (IL-5) in bone marrow and peripheral blood were quantified by double antibody sandwich enzyme-linked immunosorbent assay (ELISA), and the WES staining in the bone marrow and peripheral blood was counted. Results: The levels of IL-5 and EOS in bone marrow and peripheral blood of Xinzhi bimin capsule group were significantly lower than those in model group (P <0.05), and were statistically significant (P0.05) The EOS count of nasal mucosa in capsule group was significantly lower than that in model group and rhinitis group (P <0.01, P <0.05). Conclusion: Xinzhi bimin capsule can reduce the level of IL-5 and reduce eosinophil infiltration, and play a therapeutic role.